MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an…Read More
Chembio Stockholders Reminded to Tender Shares Before 600 PM New York City Time on April 12 2023
